Cummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., Shin, P., Tariot, P. N., Siffert, J.

IMPORTANCE: Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August […]

Quinn, Joseph F., Raman, Rema, Thomas, Ronald G., Yurko-Mauro, Karin, Nelson, Edward B., van Dyck, Christopher, Galvin, James E., Emond, Jennifer, Jack, Clifford R., Jr., Weiner, Michael, Shinto, Lynne, Aisen, Paul S

Context: Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.; Objective: To determine if supplementation with DHA slows cognitive and functional decline […]

Snitz, Beth E., O'Meara, Ellen S., Carlson, Michelle C., Arnold, Alice M., Ives, Diane G., Rapp, Stephen R., Saxton, Judith, Lopez, Oscar L., Dunn, Leslie O., Sink, Kaycee M., DeKosky, Steven T.

Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.; Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.; Design, Setting, and […]

Green, Robert C., Schneider, Lon S., Amato, David A., Beelen, Andrew P., Wilcock, Gordon, Swabb, Edward A., Zavitz, Kenton H.

Context: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial.; Objective: To determine the efficacy, safety, and tolerability of tarenflurbil.; Design, Setting, and Patients: A multicenter, randomized, double-blind, […]

Porsteinsson, Anton P., Drye, Lea T., Pollock, Bruce G., Devanand, D. P., Frangakis, Constantine, Ismail, Zahinoor, Marano, Christopher, Meinert, Curtis L., Mintzer, Jacobo E., Munro, Cynthia A., Pelton, Gregory, Rabins, Peter V., Rosenberg, Paul B., Schneider, Lon S., Shade, David M., Weintraub, Daniel, Yesavage, Jerome, Lyketsos, Constantine G.

Importance: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.; Objective: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, […]

Manson, JoAnn E., Chlebowski, Rowan T., Stefanick, Marcia L., Aragaki, Aaron K., Rossouw, Jacques E., Prentice, Ross L., Anderson, Garnet, Howard, Barbara V., Thomson, Cynthia A., LaCroix, Andrea Z., Wactawski-Wende, Jean, Jackson, Rebecca D., Limacher, Marian, Margolis, Karen L., Wassertheil-Smoller, Sylvia, Beresford, Shirley A., Cauley, Jane A., Eaton, Charles B., Gass, Margery, Hsia, Judith, Johnson, Karen C., Kooperberg, Charles, Kuller, Lewis H., Lewis, Cora E., Liu, Simin, Martin, Lisa W., Ockene, Judith K., O’Sullivan, Mary Jo, Powell, Lynda H., Simon, Michael S., Van Horn, Linda, Vitolins, Mara Z., Wallace, Robert B.

Importance: Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.; Objective: To report a comprehensive, integrated overview of findings from the 2 Women’s Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.; Design, Setting, and Participants: A total of 27,347 postmenopausal women aged 50 […]

Gitlin, Laura N, Winter, Laraine, Dennis, Marie P., Hodgson, Nancy, Hauck, Walter W.

Context: Optimal treatment to postpone functional decline in patients with dementia is not established.; Objective: To test a nonpharmacologic intervention realigning environmental demands with patient capabilities.; Design, Setting, and Participants: Prospective 2-group randomized trial (Care of Persons with Dementia in their Environments [COPE]) involving patients with dementia and family caregivers (community-living dyads) recruited from March […]

Dysken, Maurice W., Sano, Mary, Asthana, Sanjay, Vertrees, Julia E., Pallaki, Muralidhar, Llorente, Maria, Love, Susan, Schellenberg, Gerard D., McCarten, J. Riley, Malphurs, Julie, Prieto, Susana, Chen, Peijun, Loreck, David J., Trapp, George, Bakshi, Rajbir S., Mintzer, Jacobo E., Heidebrink, Judith L., Vidal-Cardona, Ana, Arroyo, Lillian M., Cruz, Angel R., Zachariah, Sally, Kowall, Neil W., Chopra, Mohit P., Craft, Suzanne, Thielke, Stephen, Turvey, Carolyn L., Woodman, Catherine, Monnell, Kimberly A., Gordon, Kimberly, Tomaska, Julie, Segal, Yoav, Peduzzi, Peter N., Guarino, Peter D.

Importance: Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.; Objective: To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.; Design, Setting, and Participants: […]